Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Manipulation of a transcriptional repressor promotes expression of protective fetal globin genes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the degree of γ -globin induction is substantially less than that seen with BCL11A de fi ciency (8).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“Reducing bcl11a expression in transgenic sickle mice derepressed g-globin genes.17,18”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [18]
In the citing paper
“However, deletion of BCL11A in mouse results in much greater increases (31.2- to 232.9-fold) of embryonic globin genes in de fi nitive fetal liver and bone marrow erythroid cells (Fig. 4 C and E ) (8)”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“Most importantly, inactivation of BCL11A alone is suf fi cient to ameliorate the hematologic and pathologic defects associated with SCD through high-level HbF induction in humanized mouse models (8).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“DNA methylation plays an important role in globin gene expression, and DNA demethylating agents have been shown to induce HbF expression in various model systems and patients (8, 17, 18).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., Brambrink, T., Wu, L.-C., Townes, T. M., et al. (2007) · Science · doi:10.1126/science.1152092 · Cited by 1,202
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Self-citationA Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell Anæmia Hæmoglobin
INGRAM, V. M. (1956) · Nature · doi:10.1038/178792a0 · Cited by 896
Direct inhibition of the NOTCH transcription factor complex
Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752
Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910.
Jb, H. (2001) · PubMed Central · Cited by 676
Cited by
Items 201–300 of 327
Gene therapy and gene editing strategies in inherited blood disorders
Song, X., Liu, J., Chen, T., Zheng, T., Wang, X., & Guo, X. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.07.004 · Cited by 18
Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.031 · Cited by 16
Wonkam, A., Makani, J., Ofori-Acquah, S. F., Nnodu, O. E., Treadwell, M., Royal, C. D. M., & Ohene‐Frempong, K. (2015) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2015-040 · Cited by 14
“Although there are several key phenotypes (anaemia, stroke, infections), foetal haemoglobin (HbF) has emerged as a central disease modifier; importantly, the expression of this modifier is amenable to therapeutic manipulation.(11,12) Genetic variants at three principal loci, BCL11A, HBS1L-MYB and the HBB cluster accou…”
BackgroundLiu, Y., Gu, Z., Cao, H., Kaphle, P., Lyu, J., Zhang, Y., Hu, W., Chung, S. S., Dickerson, K. E., & Xu, J. (2021) · Nature Communications · doi:10.1038/s41467-021-26582-4 · Cited by 14
Self-citationPharmacologic induction of PGC ‐1α stimulates fetal haemoglobin gene expression
Sun, Y., Habara, A. H., Le, C. Q., Nguyen, N., Chen, R., Murphy, G. J., Chui, D. H. K., Steinberg, M. H., & Cui, S. (2022) · British Journal of Haematology · doi:10.1111/bjh.18042 · Cited by 14
Okam, M. M., & Ebert, B. L. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.20 · Cited by 15
Self-citationPluripotent Stem Cells in Research and Treatment of Hemoglobinopathies
Arora, N., & Daley, G. Q. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011841 · Cited by 15
“There are two humanized mouse models of SCA, the “Berkeley” mouse and the “Townes” mouse, which have proven valuable in studying disease mechanisms and testing therapeutic strategies, such as gene therapy (Pawliuk et al. 2001; Xu et al. 2011).”
BackgroundLee, B.-S., Dekker, J. D., Lee, B.-K., Iyer, V. R., Sleckman, B. P., Shaffer, A. L., Ippolito, G. C., & Tucker, P. W. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00987-12 · Cited by 13
Self-citationRetractedAdelvand, P., Hamid, M., & Sardari, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1406795 · Cited by 14
“By suppressing the BCL11A in transgenic mice with SCD, the level of Hb F expression increased at a significant level that was able to correct the symptoms of the disease [75].”
BackgroundModelling human haemoglobin switching
Diepstraten, S. T., & Hart, A. H. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.06.001 · Cited by 14
Yang, H. M., Zheng, G., Li, G. Y., Alshaye, A., & Orkin, S. H. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108077 · Cited by 12
“We chose BCL11A as the POI because of its demonstrated role in fetal hemoglobin (HbF) silencing (10).”
Self-citationHeterogeneity of fetal hemoglobin production in adult red blood cells
Khandros, E., & Blobel, G. A. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000640 · Cited by 13
HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts
de Vasconcellos, J. F., Lee, Y. T., Byrnes, C., Tumburu, L., Rabel, A., & Miller, J. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166928 · Cited by 13
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Silencing of BCL11A by disrupting enhancer-dependent epigenetic insulation
Wang, K., Wang, J., Feng, R., Dudnyk, K., Kim, Y. J., Lim, J. Y. S., Lee, M., Zhang, Y., Gao, X., Cheng, Y., et al. (2025) · Blood · doi:10.1182/blood.2025030211 · Cited by 12
Self-citationYoussry, I., & Ayad, N. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05510-0 · Cited by 11
“Moreover, animal studies tested the effect of erythroid-specific knockout of BCL11A expression in mice on the enhancement of other epigenetic modifiers [33].”
Genetic Factors Modifying Sickle Cell Disease Severity
Gardner, K., & Thein, S. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-06713-1_15 · Cited by 14
Cico, A., Andrieu‐Soler, C., & Soler, É. (2016) · FEBS Letters · doi:10.1002/1873-3468.12424 · Cited by 12
Gene Editing-Based Technologies for Beta-hemoglobinopathies Treatment
Rahimmanesh, I., Boshtam, M., Kouhpayeh, S., Khanahmad, H., Dabiri, A., Ahangarzadeh, S., Esmaeili, Y., Bidram, E., Vaseghi, G., Javanmard, S. H., et al. (2022) · Biology · doi:10.3390/biology11060862 · Cited by 16
“fication in the mice with minimal effects on erythropoiesis [48].”
BackgroundLi, Y., Ding, L., Yang, C., Kang, B., Liu, L., Story, M. D., & Pace, B. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107133 · Cited by 12
“Recent human genetic studies revealed an association of mutations in the BCL11A gene and inherited HbF levels [17] which were demonstrated to be involved in the c/bglobin switch in transgenic mice [18].”
BackgroundDrakopoulou, E., Georgomanoli, M., Lederer, C. W., Panetsos, F., Kleanthous, M., Voskaridou, E., Valakos, D., Papanikolaou, E., & Anagnou, N. P. (2022) · Viruses · doi:10.3390/v14122716 · Cited by 10
“Additionally, the incorporation of small hairpin RNA (shRNA) in therapeutic globin LVs, either for simultaneous reduction in βS transcripts [25] or for down-regulation of the BCL11A expression [26], can lead to SCD phenotype correction.”
BackgroundChaand, M., Fiore, C., Johnston, B., D’Ippolito, A. M., Moon, D. H., Carulli, J. P., & Shearstone, J. R. (2023) · Communications Biology · doi:10.1038/s42003-023-05025-4 · Cited by 10
“DNA methylation is an epigenetic modi fi cation associated with HBG silencing in BM cells 22 .”
Andrieu‐Soler, C., & Soler, É. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000577 · Cited by 11
“Nevertheless, it is important to stress that, as it is the case for BCL11A [36,38] and to a lesser extent for LRF [49], HRI depletion seems to have surprisingly very little impact on erythroid cells as determined by total transcriptome and proteome analyses, making this protein an attractive target for HbF induction t…”
BackgroundGene therapy for hemoglobinopathies
Tanhehco, Y. C. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103061 · Cited by 12
“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia
Benz, E. J. J., Silberstein, L. E., & Panepinto, J. A. (2024) · Blood · doi:10.1182/blood.2023021598 · Cited by 9
Emerging cellular and gene therapies for congenital anemias
Ludwig, L. S., Khajuria, R. K., & Sankaran, V. G. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31529 · Cited by 11
“As expected, deletion of Bcl11a in a transgenic mouse model of SCD corrected the associated hematologic and pathologic defects through induction of HbF [Xu et al., 2011].”
BackgroundSelf-citationGene therapy is facing its biggest challenge yet
Ledford, H. K. (2019) · Nature · doi:10.1038/d41586-019-03698-8 · Cited by 9
DROSHA Knockout Leads to Enhancement of Viral Titers for Vectors Encoding miRNA-Adapted shRNAs
Park, H. H., Triboulet, R., Bentler, M., Guda, S., Du, P., Xu, H., Gregory, R. I., Brendel, C., & Williams, D. A. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.002 · Cited by 10
“The molecular switch from fetal to adult globin is associated with emergence of signs and symptoms of sickle cell disease (SCD) and b-thalassemias in individuals with b-globin mutations.(16,18) One therapeutic approach to treatment of b-hemoglobinopathies is the knockdown of BCL11A, which simultaneously restores g-glo…”
BackgroundGenome Editing for the β-Hemoglobinopathies
Porteus, M. H. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-7299-9_8 · Cited by 8
Mechanisms of Globin Gene Regulation in Mammals
Hardison, R. C. (2025) · Annual Review of Genetics · doi:10.1146/annurev-genet-020325-095743 · Cited by 9
“GWASs implicated variants in the BCL11A gene as contributing to elevated HbF (87, 102), and further detailed studies revealed that BCL11A is a major repressor of the HBG1,2 genes (127; 166).”
Structural insights into the DNA-binding mechanism of BCL11A: The integral role of ZnF6
Viennet, T., Yin, M., Jayaraj, A., Kim, W., Sun, Z.-Y. J., Fujiwara, Y., Zhang, K., Seruggia, D., Seo, H., Dhe‐Paganon, S., et al. (2024) · Structure · doi:10.1016/j.str.2024.09.022 · Cited by 8
Self-citationSickle cell disease (SCD), iNKT cells, and regadenoson infusion.
Nathan, D. G., Field, J. J., Lin, G., Neuberg, D. S., Majerus, E. M., Onyekwere, O. C., Keefer, J. R., Okam, M. M., Ross, A., & Linden, J. M. (2012) · PubMed · Cited by 8
Smoothing the crescent curve: sickle cell disease
Talano, J., & Cairo, M. S. (2014) · Hematology · doi:10.1182/asheducation-2014.1.468 · Cited by 9
Genetic Therapies for Sickle Cell Disease
Jayavaradhan, R., & Malik, P. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.008 · Cited by 9
Tarasev, M., Muchnik, M., Light, L., Alfano, K. M., & Chakraborty, S. (2016) · Translational research · doi:10.1016/j.trsl.2016.09.005 · Cited by 9
“Sickle cell anemia patients (SCA) are characterized by two abnormal allele of the hemoglobin beta gene (SS Hb phenotype), while sickle trait individuals (SCT) have one normal (A) one abnormal (S) allele of the hemoglobin beta gene (AS Hb phenotype).”
BackgroundInfluentialWang, Y., Yu, L., Deng, K., Packiarajan, M., Aguilar, A., An, S. Y., Liu, X., Myers, G., Oh, H., Singh, S. A., et al. (2025) · Blood · doi:10.1182/blood.2024028006 · Cited by 7
Hart, K. L., Liu, B., Brown, D., Campo-Fernández, B., Tam, K., Orr, K., Hollis, R. P., Brendel, C., Williams, D. A., & Kohn, D. B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101254 · Cited by 9
“To assess the functionality of the vectors, we transduced CD34 + cells at an MOI of 20 from two different healthy donors, each in triplicate, and performed erythroid differentiation.”
A systems pharmacology model for gene therapy in sickle cell disease
Zheng, B. J., Wille, L., Peppel, K., Hagen, D., Matteson, A., Ahlers, J. D., Schaff, J. C., Hua, F., Yuraszeck, T. M., Cobbina, E., et al. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12638 · Cited by 8
A landscape analysis and discussion of value of gene therapies for sickle cell disease
Quach, D., Jiao, B., Basu, A., Bender, M. A., Hankins, J. S., Ramsey, S. D., & Devine, B. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2060823 · Cited by 9
“[21– 23] Loss of erythroid-specific BCL11A in mouse models of SCD showed reversal of the hematologic and pathologic signs of the disease, thereby validating it as a therapeutic target[24].”
MethodFetal hemoglobin per erythrocyte ( HbF /F‐cell) after gene therapy for sickle cell anemia
Sebastiani, P., & Steinberg, M. H. (2022) · American Journal of Hematology · doi:10.1002/ajh.26791 · Cited by 7
“to be accompanied by as much as 20 pg of HbF/F-cell in studies of mice and cell lines.(15,16) In addition, 2% of cells could have less than 5 pg of HbF and not be counted as F-cells.”
BackgroundCan selectin and iNKT cell therapies meet the needs of people with sickle cell disease?
Field, J. J. (2015) · Hematology · doi:10.1182/asheducation-2015.1.426 · Cited by 7
Hay, D., & Atoyebi, W. (2016) · British Journal of Hospital Medicine · doi:10.12968/hmed.2016.77.4.c55 · Cited by 9
Inhibition of γ/β Globin Gene Switching in CD 34+ Derived Erythroid Cells by BCL11A RNA Silencing
Taghavi, S. A., Hosseini, K. M., Tamaddon, G., & Kasraian, L. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01131-8 · Cited by 7
Kansal, R. (2025) · Genes · doi:10.3390/genes16111367 · Cited by 6
“Inactivating BCL11A in genetically engineered mice reversed the pathologic effects of sickle cell disease in mice, providing further proof of BCL11A being a therapeutic target [105].”
Ropero, P., Peral, M., Sánchez-Martínez, L. J., Rochas, S., Gómez-Álvarez, M., Nieto, J. M., González, F. A., Villegas, A., & Benavente, C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1347026 · Cited by 8
Kits for RNA Extraction, Isolation, and Purification
Johnson, M. (2012) · Materials and Methods · doi:10.13070/mm.en.2.201 · Cited by 9
Phyto-Medicine in Gene(s) Targeting Future Direction for Sickle Cell Disease Management
Alli, L. A., & Okoh, M. P. (2016) · Hereditary Genetics · doi:10.4172/2161-1041.1000169 · Cited by 7
“Such technology used on wild type - globin gene was shown [10,36], to be suited for treating -thalassemia.”
BackgroundMethodInfluentialChen, W.-R., Chou, C., & Wang, C. C. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019031120 · Cited by 6
“Fetal hemoglobin (HbF) induction therapy has become the most promising strategy for treating b-hemoglobinopathies, including sickle cell diseases and b-thalassemia.(1-14) However, despite their common oxygen-carrying capabilities, critical structural difference exists between HbF and normal adult hemoglobin (HbA), pre…”
BackgroundIs There a Role for Pharmacogenetics in the Treatment of Sickle Cell Disease?
Wonkam, A. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0007 · Cited by 6
Role of gene therapy in sickle cell disease
Raghuraman, A., Lawrence, R., Shetty, R., Avanthika, C., Jhaveri, S., Pichardo, B. V., & Mujakari, A. (2024) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101689 · Cited by 7
N-ethylmaleimide activates a Cl−-independent component of K+ flux in mouse erythrocytes
Shmukler, B. E., Hsu, A., Alves, J., Trudel, M., Rust, M. B., Hübner, C. A., Rivera, A., & Alper, S. L. (2013) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.02.004 · Cited by 5
“Pharmacological blockade of these leak pathways remains a therapeutic goal for the adjunct treatment of SCD [3; 4; 5], envisioned as combination therapy with inducers of HbF [6; 7; 8] and likely also with blockers of sickle cell adhesion to activated endothelial cells [9].”
BackgroundInnovations in Targeted Anti‐Adhesion Treatment for Sickle Cell Disease
Kanter, J., & Lanzkron, S. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1682 · Cited by 5
“Hydroxyurea, like other chemotherapeutic medications, redirects erythrocyte progenitors to produce fetal Hb in place of HbS. Specific pharmacogenetic analysis has demonstrated that there are specific polymorphisms of BCL11A, which may predict the expression of fetal Hb.15,16 Because polymerization of the HbS is a key…”
BackgroundDirect and indirect regulation of fetal globin transcript by the RNA-binding protein IGF2BP1
Coyne, S. M., Hwang, G.-H., Wu, T., Hossain, M. A., Vinjamur, D. S., Starrs, M. M., Zeng, J., Andresen, F., Gutierrez, A. M., Shimamura, A., et al. (2026) · Blood · doi:10.1182/blood.2025031840 · Cited by 5
Current therapeutic landscape of β-thalassemia: focus on gene therapy
Cheng, A. N., & Kwiatkowski, J. L. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261433028 · Cited by 4
“23,24 Furthermore, the protective effect of fetal hemoglobin is clinically evident, as anemia and symptoms of thalas-semia and sickle cell disease do not typically develop before 3 months of age, when HbF levels are physiologically high.”
Future Perspectives for the Treatment of Sickle Cell Anemia
Nottage, K. A., Estepp, J. H., & Hankins, J. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-06713-1_16 · Cited by 4
Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis
Zhang, H., Zeng, J., Zhang, F., Liu, J., & Liang, L. (2025) · Biology · doi:10.3390/biology14010026 · Cited by 5
Fan, A. X., Hossain, M. A., Stees, J. R., Gavrilova, E. V., & Bungert, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-799958-6.00011-1 · Cited by 7
BCL11A rs1427407 Genotypes in Sickle Cell Anemia Patients Undergo to Stroke Problems in Sudan
Hassan, F. M., & Alzahrani, F. (2018) · Korean Journal of Family Medicine · doi:10.4082/kjfm.17.0144 · Cited by 4
Johnson, M. (2013) · Materials and Methods · doi:10.13070/mm.en.3.193 · Cited by 5
The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment
Lai, M. I., & Ahmed, N. H. M. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x23666230123140926 · Cited by 4
Inpatient Management of Sickle Cell Disease
Hunt, S., & Alisky, J. M. (2012) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2012.11.001 · Cited by 4
Perspective: A novel prognostic for sickle cell disease
Mozeleski, B., Al‐Rubaish, A. M., Al‐Ali, A. K., & Romero, J. R. (2018) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_107_18 · Cited by 4
“In transgenic sickle mice, inactivation of BCL11A nullified the complications of the disease.[32] It should be noted that these animals have homogeneous distributions of HbF, similar to HbS–HPFH, where pancellular distribution of HbF was adequate to prevent polymer‐induced damage.”
MYB represses ζ-globin expression through upregulating ETO2
Dong, Z., Ye, Y., Zhang, W., Luo, H., Li, J., Zhang, Q., Zhang, X., Guo, X., & Xu, X. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024239 · Cited by 3
“Recent studies provided evidence that BCL11A and LRF, two master γ - globin regulators, might have a direct effect on ζ - globin repression, both by associating with NuRD complex and possibly recruiting HDAC proteins as well [22–24].”
Buccheri, M. A., Spina, S., Ruberto, C., Lombardo, T., Labie, D., & Ragusa, A. (2013) · Hemoglobin · doi:10.3109/03630269.2013.800823 · Cited by 4
miR-365-3p mediates BCL11A and SOX6 erythroid-specific coregulation: A new player in HbF activation
Simbula, M., Manchinu, M. F., Mingoia, M., Pala, M., Asunis, I., Caria, C. A., Perseu, L., Shah, M., Crossley, M., Moi, P., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.09.002 · Cited by 3
“54 The g -globin gene is a validated target for treating b -thalassemia and SCD. 7,13 The ε -globin gene appears to be an excellent anti-sickling agent in SCD in vivo .”
BackgroundGene Therapy for Hemoglobinopathies
Dong, A., Breda, L., & Rivella, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00012-9 · Cited by 4
BCL11Acontrôle l’expression de l’hémoglobine fœtale
Labie, D. (2012) · médecine/sciences · doi:10.1051/medsci/20122811007 · Cited by 4
Using the hemoglobin switch for the treatment of sickle cell disease
Cools, J. (2012) · Haematologica · doi:10.3324/haematol.2012.062190 · Cited by 3
“In a study published in the November 18 issue of Science, Xu and colleagues(7) used a sickle cell disease mouse model to demonstrate that interference with BCL11A function in vivo in the mouse could increase fetal hemoglobin levels, and thereby reduce the severity of the disease in that model.(7) Since BCL11A null mic…”
BackgroundConsensus Predictive Model for Human K562 Cell Growth Inhibition through Enalos Cloud Platform
Afantitis, A., Leonis, G., Gambari, R., & Melagraki, G. (2017) · ChemMedChem · doi:10.1002/cmdc.201700675 · Cited by 3
High-efficiency HDR in immortalized cell lines by crude rAAV mediated donor template deliveryPreprint
Mehta, S., Buyanbat, A., Zheng, G., Liu, N., & Orkin, S. H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.02.490359 · Cited by 3
“BCL11A is a zinc-finger transcription factor that is a critical repressor of γ-globin genes in adult erythrocytes [25-28], and also important for B-lymphocyte and nervous system development [29, 30].”
BackgroundSelf-citationAyuba, S. A., Bashar, F., & Abbas, A. Y. (2025) · International Journal of Epigenetics · doi:10.3892/ije.2025.29 · Cited by 2
“The selective erythroid deletion of BCL11A in mice has shown promise in the treatment of SCA (22), leading to clinical studies using genome modification with promising outcomes (23,24).”
Wu, J., Yang, F., Du, X., Shi, S., Li, L., Wang, Z., Wang, J., Yi, C., Duan, Y., Xiao, Y., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117449 · Cited by 2
Investigating the missing heritability of fetal haemoglobin level in Africa
Wonkam, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.17101 · Cited by 3
“High foetal haemoglobin (HbF) levels have long been associated with less severity,(1) yet, HbF levels are under genetic control(2) and have been shown to be amenable to therapeutic manipulation in a murine model.(3) Genes and loci that control HbF levels, for example, BLL11A, a transcriptional repressor of HbF, are cr…”
BackgroundCui, M., Billett, H. H., Suzuka, S. M., Ambadipudi, K., Archarya, S., Mowrey, W. B., & Branch, C. A. (2022) · Translational research · doi:10.1016/j.trsl.2022.01.003 · Cited by 2
From genome-wide association study hits to new insights into experimental hematology
Cvejic, A. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.04.005 · Cited by 2
2015 ASHG Awards and Addresses
(2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.01.013 · Cited by 2
Gentherapie von Hämoglobinkrankheiten – aktuelle Konzepte und Herausforderungen
Kulozik, A. E., & Kunz, J. B. (2019) · Transfusionsmedizin · doi:10.1055/a-0825-9666 · Cited by 2
The long road to the cure of sickle cell anemia: Reflections on race and medicine in America
Appiah‐Kubi, A., & Lipton, J. M. M. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24035 · Cited by 2
“[2] exploits this knowledge and, to the optimistic, suggests a molecular approach to treatment may be near.”
BackgroundMolecular scissors cut in on stem cells
Azvolinsky, A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0467-6 · Cited by 2
Fetal Hemoglobin Research and Clinical Relevance in Sickle Cell Disease
Gudmundsdóttir, B. K., & Tisdale, J. F. (2025) · Physiology · doi:10.1152/physiol.00024.2025 · Cited by 1
Genetic influences on haematopoiesis
Poeschla, M., & Sankaran, V. G. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00947-1 · Cited by 3
“As such, BCL11A was nominated as a therapeutic target to reactivate HbF in sickle cell disease and β-thalassaemia 253–255 , further supported by the observation that rare haploinsufficient variants in BCL11A were found to significantly elevate fetal haemoglobin levels 256,257 .”
Self-citationPrinciples of Cell-Based Genetic Therapies
Williams, D. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00098-6 · Cited by 2
Reactivation of Fetal Hemoglobin in Thalassemia and Sickle Cell Disease
Eridani, S., Avemaria, F., & Mosca, A. (2014) · Thalassemia Reports · doi:10.4081/thal.2014.2196 · Cited by 4
Chang, K., Huang, A., Han, H., Jiang, Y., Fang, X., Song, C.-Z., Padilla, S., Wang, H., Qu, H., Stamatoyannopoulos, J. A., et al. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.08.005 · Cited by 2
“The reactivation of γ globin in adult erythroid cells in vitro and/or in vivo via knocking down γ globin repressors, such as Bcl11A and EKLF, is well documented [21, 30, 50].”
BackgroundPrecision Medicine for Sickle Cell Disease: Discovery of Genetic Targets for Drug Development
Pace, B. S., Lopez, N. H., Zhu, X., & Li, Y. (2016) · InTech eBooks · doi:10.5772/64817 · Cited by 1
“globin gene repression during murine development and correction of the SCD phenotype [119].”
BackgroundTaebi, S., Eskandari, F., Kohandani, M., Manoochehrabadi, T., & Nasiri, H. (2025) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v19i4.19988 · Cited by 2
Arora, M. (2013) · Materials and Methods · doi:10.13070/mm.fr.3.175 · Cited by 1
The generation of a Bcl11a lineage tracing mouse modelPreprint
Pensa, S., Liu, P., & Khaled, W. T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.26.453822 · Cited by 1
Genomic Characterization of Sickle Cell Mouse Models for Therapeutic Genome Editing Applications
Woodard, K. J. (2021) · doi:10.21007/etd.cghs.2021.0540 · Cited by 2
Apte, S. (2016) · International Journal of Pharmaceutical Excipients · doi:10.66617/001c.1090
Correction of sickle cell disease in mice by knock-out of BCL11A
Labie, D. (2011) · Hématologie · doi:10.1684/hma.2011.0657
“Orkin, du département d’oncologie pédiatrique à Harvard [3].”
Globin gene regulation for treating β-thalassemias: progress, obstacles and future
Saliba, A. N., Alameddine, R. S., Harb, A., & Taher, A. T. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1074071
“Therefore, downregulation of BCL11A leads to increased HbF expression in adult human erythroid cells [41,55].”
Background2014 William Allan Award: A Hematologist’s Pursuit of Hemoglobin Genetics1
Orkin, S. H. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.12.007
“Through a series of studies in cells and mice, my group has validated BCL11A as a central regulator of Hb switching in mice and HbF silencing in humans.(18,19) Dial BCL11A up, and HbF is reduced; dial down BCL11A, and HbF is increased (Figure 7).”
BackgroundSelf-citationThe Role of ZBP-89 in Globin Regulation
Aghajanirefah, A. (2012) · RePub (Erasmus University Rotterdam)
Complex Disease Genes and Their Discovery
Barrett, J. C., & Daly, M. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8256-7_4
“This discovery was followed by the remarkable discovery that reducing the activity of BCL11A could substantially alleviate SCD in mice [ 38 ].”
BackgroundThe State of the Field and the Future
Chandrakasan, S., & Malik, P. (2014)
Elucidation of Mechanisms of Fetal Hemoglobin Regulation by CRISPR/Cas9 Mediated Genome Editing
Canver, M. C. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Zon, L. I. (2018) · Journal of Clinical Investigation · doi:10.1172/jci124493
Metadata
- Authors
- Xu, J., Peng, C., Sankaran, V. G., Shao, Z., Esrick, E. B., Chong, B. G., Ippolito, G. C., Fujiwara, Y., Ebert, B. L., Tucker, P. W., & Orkin, S. H.
- Affiliations
- Boston Children's Hospital (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- The University of Texas at Austin (US)
- Corresponding author
- Peng, Cong
- Sankaran, Vijay G.
- Orkin, Stuart H.
- ORCID
- Venue
- Science
- Published
- 2011-11-18
- Volume
- 334
- Issue
- 6058
- Pages
- 993-996
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3746545
- OpenAlex
- W2033380734
- Cited by
- 326
- References
- 45
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 20 · 2020: 22 · 2019: 18 · 2018: 25 · 2017: 24 · 2016: 42 · 2015: 26 · 2014: 23 · 2013: 32 · 2012: 19
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (T32CA009172)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK093543)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- sickle cell disease, fetal hemoglobin, BCL11A, beta-thalassemia, transgenic mice, therapeutic target, erythropoiesis
- MeSH terms
- Anemia, Sickle Cell, Animals, Carrier Proteins, DNA-Binding Proteins, Embryo, Mammalian, Fetal Hemoglobin, Gene Expression Regulation, Histones, Humans, Mice, Transgenic, Nuclear Proteins, Repressor Proteins, Mice, Knockout, DNA Methylation, Gene Silencing, Erythroid Cells, Epigenesis, Genetic, Mice, gamma-Globins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.